ASML reports €5.3 billion total net sales and €1.2 billion net income in Q1 2024

ASML reports €5.3 billion total net sales and €1.2 billion net income in Q1 2024

ASML reports €5.3 billion total net sales and €1.2 billion net income in Q1 20242024 outlook unchanged VELDHOVEN, the Netherlands, April 17, 2024 – Today, ASML Holding NV (ASML) has published its 2024 first-quarter results. Q1 total net sales of €5.3 billion, gross margin of 51.0%, net income of €1.2 billion Quarterly net bookings in Q1 of €3.6 billion2 of which €656 million is EUV ASML expects Q2 2024 total net sales between €5.7 billion and €6.2 billion, and a gross margin between 50% and 51% ASML expects 2024 total net sales to be similar to 2023 (Figures in millions of euros unless otherwise indicated) Q4 2023   Q1 2024   Total net sales 7,237   5,290   …of which Installed Base Management sales1 1,555   1,324             New lithography...

Continue reading

Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis

Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis

Continuous Kesimpta® treatment for up to six years showed sustained efficacy in recently diagnosed (≤3 years) treatment-naïve people living with relapsing multiple sclerosis (RMS) in an analysis of the ALITHIOS open-label extension study1 Similar efficacy outcomes were demonstrated in a separate analysis of continuous Kesimpta treatment for up to six years in the overall ALITHIOS study population2 Switch from teriflunomide to Kesimpta resulted in significant improvements across several efficacy outcomes such as annualized relapse rate and MRI lesion activity in both analyses1,2 Treatment with Kesimpta for up to six years continues to be well tolerated with consistent safety outcomes, supporting the favorable benefit-risk profile of Kesimpta in RMS2 Basel, April 17, 2024 – Novartis today announced data from the ALITHIOS open-label...

Continue reading

TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering

TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering

WALTHAM, Mass., April 17, 2024 (GLOBE NEWSWIRE) — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the pricing of an underwritten public offering of 2,472,581 shares of its voting common stock at a public offering price of the market price of $7.1300 per share, which was equal to the closing price of its voting common stock on the Nasdaq Global Market on April 16, 2024, and pre-funded warrants to purchase up to an aggregate of 18,577,419 shares of its voting common stock at a price to the public of $7.1299 per pre-funded warrant to purchase one share of the voting common stock, which represents the per share public offering price for the voting common...

Continue reading

Feintool wins important contract in Europe’s hydrogen industry

Feintool wins important contract in Europe’s hydrogen industry

The company is tasked with the production of high-precision metal components for fuel cells and electrolyzers. This successfully marks Feintool’s entry into the European market, following the company’s nomination in China by a leading market player. The contract, which was awarded by a renowned European company specializing in fuel cells and electrolysers, involves the series supply of several components, including high-precision flow field plates. Initially, the order volume is expected to reach several million euros per year. «Feintool is investing in Europe’s energy future with hydrogen technology and making an important contribution to environmental sustainability. The new contract confirms our strategy of focusing on future markets within the green energy sector.» Torsten Greiner, CEO Feintool. Collaboration between partners This...

Continue reading

Insurance leaders optimistic about AI’s impact on underwriting quality and fraud reduction but underwriter confidence lags

Insurance leaders optimistic about AI’s impact on underwriting quality and fraud reduction but underwriter confidence lags

Press Contact: Fahd Pasha Tel.: +1 647 860 3777 E-mail: Fahd.Pasha@capgemini.com  Insurance leaders optimistic about AI’s impact on underwriting quality and fraud reduction but underwriter confidence lags 62% of insurance executives recognize artificial intelligence/machine learning technology (AI/ML) as elevating underwriting quality and reducing fraud 43% of underwriters trust and regularly accept automated recommendations from predictive analytics tools but many still have concerns around complexity and data integrity Paris, April 17, 2024 – The Capgemini Research Institute’s World Property and Casualty Insurance Report 2024, published today, reveals the underwriting capabilities of insurers are being restricted by organizational constraints. According to the report, only 8% of property and casualty (P&C) insurers are regarded...

Continue reading

TokenEx and IXOPAY to Merge, Enabling Merchants to Optimize the Use of Multiple Payment Processors

TokenEx and IXOPAY to Merge, Enabling Merchants to Optimize the Use of Multiple Payment Processors

Payments Optimization Platform for Global Commerce Delivers Omnichannel Tokenization, Payments Orchestration, and Card Lifecycle Management TULSA, Okla. and VIENNA, Austria, April 17, 2024 (GLOBE NEWSWIRE) — TokenEx, the leading cloud tokenization provider, and IXOPAY, the leading independent payments orchestration platform, today are announcing their definitive agreement to merge, creating a new leader in global payments optimization. The combined company will be called IXOPAY, a TokenEx Company, and Marc Olesen will lead the combined organization as CEO. Customers will benefit from a comprehensive platform that enables increased authorization rates and decreased interchange fees for merchants, along with PCI-certified secure payment data. This merger brings together the strengths of TokenEx’s expertise in tokenization of payment...

Continue reading

Convening Notice for Annual General Meeting and Extraordinary General Meeting of Shareholders

Convening Notice for Annual General Meeting and Extraordinary General Meeting of Shareholders

Convening Notice for Annual General Meeting and Extraordinary General Meeting of Shareholders MILLICOM INTERNATIONAL CELLULAR S.A.Registered Address: 2, Rue du Fort BourbonL-1249 Luxembourg, Grand Duchy of Luxembourg– R.C.S. Luxembourg: B 40.630 –                                                                                                      I.          NOTICE The annual general meeting (“AGM”) and subsequent extraordinary general meeting (“EGM”) of the shareholders of MILLICOM INTERNATIONAL CELLULAR S.A. (“Millicom” or the “Company”) is hereby convened to be held at Hotel Le Royal, 12 Bd Royal, 2449 Luxembourg on Thursday, May 23, 2024, at 11:00 a.m. Central European Time (“CET“). To attend the AGM and EGM or vote by proxy, please follow the instructions in section IV: “Right to participate at the AGM and the EGM”. The...

Continue reading

Millicom’s Nomination Committee’s proposal for Board of Directors

Millicom’s Nomination Committee’s proposal for Board of Directors

Millicom’s Nomination Committee’s proposal for Board of Directors Luxembourg, April 17, 2024 – In advance of the Annual General Meeting of shareholders (“AGM”) of Millicom International Cellular S.A. (“Millicom”), to be held on May 23, 2024, Millicom’s Nomination Committee proposes: The election of Maxime Lombardini and Justine Dimovic as new Directors of the Board; The re-election of María Teresa Arnal Machado, Bruce Churchill, Aude Durand, Tomas Eliasson, Mauricio Ramos, Thomas Reynaud, and Blanca Treviño de Vega as Directors of the Board; and the election of Mauricio Ramos as Chair of the Board. Pernille Erenbjerg and Michael Golan have decided not to seek re-election. Maxime Lombardini will bring his extensive experience and track record in leading businesses in the telecommunications industry, as well as the strong knowledge of...

Continue reading

<div>Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316</div>

Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316

WATERTOWN, Mass., April 16, 2024 (GLOBE NEWSWIRE) — Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), today announced it will be holding a virtual corporate R&D event on April 24th, 2024 from 4:15 p.m. to 5:30 p.m. ET. The agenda will feature presentations by Acrivon’s leadership team followed by an interactive Q&A session. “We are very excited to share key updates across our AP3-driven pipeline and to highlight the power of employing our precision phosphoproteomics-based approach...

Continue reading

Beam Global Reports Record Year End 2023 Operating Results

Beam Global Reports Record Year End 2023 Operating Results

Conference Call Wednesday April 17, 2024 at 4:30 p.m. ET SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) — Beam Global, (Nasdaq: BEEM, BEEMW), (the “Company”), the leading provider of innovative and sustainable infrastructure solutions for the electrification of transportation and energy security, today announced operating results for the year ended December 31, 2023. 2023 and Recent Company Highlights Record full year revenues of $67.4 million, 206% year over year increase Record Q4 revenues of $20.0 million, 154% year over year increase and highest quarterly revenue in the company’s history Record full year EV ARC™ system production, 194% year over year increase Positive full-year gross profit – an improvement of 9% as a percentage of revenue over 2022 Debt free and $100 million line of credit available and unused Current pipeline...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.